Mucosal Atomization Device Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Mucosal Atomization Device Market size was valued at USD 712.3 million in 2023 growing at a CAGR of 7.4% between 2024 and 2032. The market growth is being fuelled by several key factors, including the rising prevalence of respiratory illnesses, expanding adoption of intranasal drug delivery systems, and a surging demand for safer and pain-free medication administration solution. Furthermore, the ease of handling and precise drug delivery facilitated by mucosal atomization devices are bolstering market expansion efforts.
With the increasing prevalence of respiratory conditions such as chronic sinusitis, allergic rhinitis, asthma, and respiratory infections, there is a growing need for effective delivery methods for respiratory medications. Mucosal atomization devices provide a targeted medication delivery method that directly applies the drugs to the respiratory mucosa, enhancing the treatment results for patients with respiratory conditions. According to a study published in National Library of Medicine in April 2022, prevalence of allergic rhinitis has increased globally since the 1990 affecting about 400 million people worldwide yearly.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Mucosal Atomization Device Market Size in 2023: | USD 712.3 Million |
Forecast Period: | 2024 to 2032 |
Forecast Period 2023 - 2032 CAGR: | 7.4 |
2023 Value Projection: | USD 1.3 Billion |
Historical Data for: | 2021 - 2023 |
No of Pages: | 190 |
Tables, Charts & Figures: | 291 |
Segments Covered: | Product Type, Technology, End User, and Region |
Growth Drivers: |
|
Pitfalls Challenges: |
|
Based on the product type, the global mucosal atomization device market is classified into nasal atomization devices, fiber optic atomization devices, laryngo tracheal atomization devices, and bottle atomizers. The nasal atomization devices segment dominated the global market by securing a significant share of about 36.6% in 2023.
Based on the technology, the mucosal atomization device market is classified into gas propelled atomization devices and electrical atomization devices. The gas propelled atomization devices segment held the largest market share of 78.2% in 2023.
Based on the end user, the mucosal atomization device market is classified into hospitals, ambulatory surgery centers, and speciality clinics. The hospital segment is expected to reach USD 606.2 million by the end of 2032.
North America region is projected to maintain its dominance in the global mucosal atomization device market and is anticipated to reach USD 498.9 million by 2032.
U.S. mucosal atomization device market was valued at USD 242.9 million in 2023.
UK has emerged as a key player in the mucosal atomization device market in Europe, showcasing significant growth potential.
China mucosal atomization device industry is anticipated to witness lucrative growth between 2024 – 2032. Increasing prevalence of respiratory illness, availability of low-cost mucosal atomization devices, and growing awareness towards safe and precision drug delivery options is fuelling the adoption of mucosal atomization devices in China.
The mucosal atomization device industry is moderately concentrated with the presence of few established market players. Strategic partnership and product enhancements are the key strategies being adopted by the market players to gain competitive edge over their rivals.
Prominent players operating in the mucosal atomization device industry are as mentioned below:
Market, By Product Type
Market, By Technology
Market, By End User
The above information is provided for the following regions and countries:
Mucosal atomization device industry size recorded over USD 712.3 million in 2023 and is expected to depict 7.4% CAGR from 2024 to 2032, owing to the rising prevalence of respiratory illnesses, and the expanding adoption of intranasal drug delivery systems
The nasal atomization devices segment in the market accumulated 36.6% share in 2023 and is estimated to grow at substantial CAGR between 2024 and 2032, on account of the surging incidences of respiratory illness.
North America mucosal atomization device industry is projected to be worth USD 498.9 million by 2032, due to the robust presence of advanced healthcare facilities, high demand for non-invasive drug delivery solutions, and the increasing cases of respiratory illness.
Becton, Dickinson, and Co., BTME Group Ltd. (Medtree), BVM Meditech Pvt. Ltd., Cook Medical, Inc., DeVilbiss Healthcare LLC, Intersurgical Ltd., Kurve Therapeutics, Life-Assist Inc., Medica Holdings, LLC, Medspray, Pulmodyne, Inc., and Teleflex Inc. are some of the leading mucosal atomization device companies worldwide.